Clinical Trials Browser

Phase 1/2 × Lymphoma × Antigens, CD19 × Clear all

NCT05651100 2022-12-14

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Phase 1/2 Unknown

Lymphoma, Lymphoma, B-Cell